PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Ketamine Versus Pregabalin for Opioid Sparing After Spinal Fusion

★ Editor's Pickketaminepregabalingabapentinoidsopioid sparingspinal fusionpostoperative painERASnetwork meta-analysismedication safetymultimodal analgesia Perioperative / Anesthesia

Background Information

Ketamine might outperform pregabalin in reducing opioid use post-spinal fusion.

Spinal fusion surgery results in significant postoperative pain and high opioid usage, posing a risk for adverse events. Comparing ketamine and pregabalin's effectiveness helps optimize pain management. Ketamine decreased 24-hour opioid use compared to pregabalin 150 mg, but pregabalin 300 mg showed no significant difference. Pain scores were similar across groups. Ketamine may offer more opioid reduction, but findings are imprecise. Larger, direct head-to-head studies are needed to confirm efficacy and safety. Ketamine may provide better opioid-sparing effects than pregabalin in spinal fusion cases.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Coffin M, Azhar MZ, Shepherd W, McGrath K, Garner R, Cornea C, Cheng J, Virojanapa J

Citation: Coffin M, Azhar MZ, Shepherd W, et al. Comparison of Ketamine and Pregabalin on Postoperative Opioid Usage and Pain Management in Spinal Fusion: Systematic Review and Network Meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2026;153:112239. doi:10.1016/j.jocn.2026.112239

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.